The trial was not designed to test whether psilocybin is equivalent to escitalopram.
This effort makes the compound available for clinical trials.
The research team was led by Dr. Adam Klein
The discovery reported by Kim at al. in the journal Cell sheds light on how compounds interact with and activate this canonical receptor.
MindMed and Liechti Lab join forces for a first-of-its-kind psychedelic clinical trial.
This technology may help ease some of the concerns surrounding psychedelic therapy.
This is the first scientific evidence that anything but psilocybin or psilocin could potentially contribute to the pharmacology of magic mushrooms.
Researchers isolate ayahuasca-like compounds known as ß-carbolines from several species of Psilocybe.
Researchers used PET scans, blood psilocin levels, and subjective effects to verify that psilocin binding to 5-HT2A receptors causes the psychedelic experience.
Researchers find that psilocybin changes blood flow, communication pathways, and activity in the brain, enabling "a state of unconstrained cognition."
Researchers find the psychosis produced from psilocybin in humans is due to activation of serotonin 2A receptors.